{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,8]],"date-time":"2026-07-08T14:41:55Z","timestamp":1783521715329,"version":"3.55.0"},"reference-count":13,"publisher":"American Society of Hematology","issue":"21","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"DOI":"10.1182\/bloodadvances.2025017583","type":"journal-article","created":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:31:14Z","timestamp":1762878674000},"page":"5651-5653","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":1,"title":["Beyond the CAR-T horizon in mantle cell lymphoma"],"prefix":"10.1182","volume":"9","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-6804-2432","authenticated-orcid":false,"given":"Thomas E.","family":"Lew","sequence":"first","affiliation":[{"name":"1Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2188-6835","authenticated-orcid":false,"given":"John F.","family":"Seymour","sequence":"additional","affiliation":[{"name":"1Clinical Haematology, Peter MacCallum Cancer Centre and Royal Melbourne Hospital, Melbourne, VIC, Australia"},{"name":"2University of Melbourne, Parkville, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","published-online":{"date-parts":[[2025,11,11]]},"reference":[{"issue":"21","key":"2025111111310911400_bib1","doi-asserted-by":"crossref","first-page":"5654","DOI":"10.1182\/bloodadvances.2025016315","article-title":"Treatment patterns and outcomes following progression of disease post-CAR-T therapy in relapsed or refractory mantle cell lymphoma: a multicenter analysis","volume":"9","author":"Epstein-Peterson","year":"2025","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2025111111310911400_bib2","doi-asserted-by":"crossref","first-page":"4388","DOI":"10.1182\/blood-2024-198018","article-title":"Five-year outcomes of patients (Pts) with relapsed\/refractory mantle cell lymphoma (R\/R MCL) treated with brexucabtagene autoleucel (Brexu-cel) in ZUMA-2 cohorts 1 and 2","volume":"144","author":"Wang","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2025111111310911400_bib3","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1200\/JCO.21.02370","article-title":"Three-year follow-up of KTE-X19 in patients with relapsed\/refractory mantle cell lymphoma, including high-risk subgroups, in the ZUMA-2 study","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"14","key":"2025111111310911400_bib4","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.22.01797","article-title":"Brexucabtagene autoleucel for relapsed or refractory mantle cell lymphoma in standard-of-care practice: results from the US Lymphoma CAR T Consortium","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"20","key":"2025111111310911400_bib5","doi-asserted-by":"crossref","first-page":"2127","DOI":"10.1182\/blood.2022016040","article-title":"Single-cell multiomics reveal the scale of multilayered adaptations enabling CLL relapse during venetoclax therapy","volume":"140","author":"Thijssen","year":"2022","journal-title":"Blood"},{"issue":"10","key":"2025111111310911400_bib6","doi-asserted-by":"crossref","first-page":"2516","DOI":"10.3390\/cancers14102516","article-title":"Glofitamab treatment in relapsed or refractory DLBCL after CAR T-cell therapy","volume":"14","author":"Rentsch","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"15","key":"2025111111310911400_bib7","doi-asserted-by":"crossref","first-page":"3955","DOI":"10.1182\/bloodadvances.2024015719","article-title":"Outcomes of bispecific antibody therapy after CAR T-cell failure in relapsed\/refractory large B-cell lymphoma","volume":"9","author":"Shumilov","year":"2025","journal-title":"Blood Adv"},{"issue":"24","key":"2025111111310911400_bib8","doi-asserted-by":"crossref","first-page":"3988","DOI":"10.1200\/JCO.23.00562","article-title":"Pirtobrutinib in covalent Bruton tyrosine kinase inhibitor pretreated mantle-cell lymphoma","volume":"41","author":"Wang","year":"2023","journal-title":"J Clin Oncol"},{"issue":"2","key":"2025111111310911400_bib9","doi-asserted-by":"crossref","first-page":"e68","DOI":"10.3324\/haematol.2018.198812","article-title":"Efficacy of venetoclax monotherapy in patients with relapsed, refractory mantle cell lymphoma after Bruton tyrosine kinase inhibitor therapy","volume":"104","author":"Eyre","year":"2019","journal-title":"Haematologica"},{"issue":"11","key":"2025111111310911400_bib10","doi-asserted-by":"crossref","first-page":"2857","DOI":"10.1038\/s41409-021-01418-3","article-title":"T-cell replete allogeneic stem cell transplant for mantle cell lymphoma achieves durable disease control, including against TP53-mutated disease","volume":"56","author":"Lew","year":"2021","journal-title":"Bone Marrow Transplant"},{"issue":"11","key":"2025111111310911400_bib11","doi-asserted-by":"crossref","first-page":"1792","DOI":"10.1080\/10428194.2023.2241095","article-title":"Allogeneic stem cell transplantation achieves long-term remissions in mantle cell lymphoma, including in TP53-mutated disease","volume":"64","author":"Lew","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"6","key":"2025111111310911400_bib12","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1111\/bjh.15721","article-title":"Allogeneic haematopoietic cell transplantation impacts on outcomes of mantle cell lymphoma with TP53 alterations","volume":"184","author":"Lin","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"2025111111310911400_bib13","doi-asserted-by":"crossref","first-page":"e142","DOI":"10.1016\/S2352-3026(22)00355-6","article-title":"Treatment approaches for patients with TP53-mutated mantle cell lymphoma","volume":"10","author":"Lew","year":"2023","journal-title":"Lancet Haematol"}],"container-title":["Blood Advances"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5651\/2419787\/blooda_adv-2025-017583-c-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article-pdf\/9\/21\/5651\/2419787\/blooda_adv-2025-017583-c-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T16:31:16Z","timestamp":1762878676000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/bloodadvances\/article\/9\/21\/5651\/548103\/Beyond-the-CAR-T-horizon-in-mantle-cell-lymphoma"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,11]]},"references-count":13,"journal-issue":{"issue":"21","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1182\/bloodadvances.2025017583","relation":{},"ISSN":["2473-9529","2473-9537"],"issn-type":[{"value":"2473-9529","type":"print"},{"value":"2473-9537","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2025,11,11]]},"published":{"date-parts":[[2025,11,11]]}}}